Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 27

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 27
---
 69,375 |     | $                    | 29,151 |     | $                    |  57,099 |     | $     | 155,625 |

(1) Mr. Kaseta was appointed as a member of the Board effective November 4, 2024, and his cash compensation was prorated for his partial year of service.

18

These columns reflect the aggregate grant date fair value of equity awards granted in 2024 and calculated in accordance with FASB ASC Topic 718, excluding the effects of estimated forfeitures. The assumptions used are included in our Annual Report on Form 10-K for the year ended December 31, 2024.

Initial option awards vest monthly over a four-year period from the date of grant. Initial stock awards vest quarterly over a four-year period from the date of grant. Annual option awards vest monthly over a one-year period from the date of grant (which was January 19, 2024). Annual stock awards vest after one year from the date of grant (which was January 19, 2024). Mr. Kaseta received his initial awards (which was granted on November 4, 2024) and did not receive annual awards. All the other non-employee directors received annual awards.

The aggregate number of shares subject to outstanding stock options held by each director listed in the table above as of December 31, 2024 was as follows: 219,248 shares for Dr. Dissanaike, 355,748 shares for Mr. Johnson, 227,272 shares for Mr. Kaseta, 310,957 shares for Mr. Morgan, 219,248 shares for Ms. Rodriguez and 295,023 shares for Mr. Waage. In addition, the shares subject to outstanding unvested restricted stock units as of December 31, 2024 was as follows: 15,120 shares for Dr. Dissanaike, 13,948 shares for Mr. Johnson, 37,879 shares for Mr. Kaseta, 35,255 shares for Mr. Morgan, 15,120 shares for Ms. Rodriguez and 13,948 shares for Mr. Waage.

19

<div align='center'>COMMUNICATIONS WITH DIRECTORS</div>

Stockholders and other interested parties may communicate with the Board by sending a letter to Heron’s Board of Directors, c/o Corporate Secretary, 100 Regency Forest Drive, Suite 300, Cary, North Carolina, 275